These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 37899131)

  • 21. Engineering Cell Lines for Specific Human Leukocyte Antigen Presentation.
    Jin D; Loh KL; Shamekhi T; Ting YT; Lim Kam Sian TCC; Roest J; Ooi JD; Vivian JP; Faridi P
    Methods Mol Biol; 2023; 2691():351-369. PubMed ID: 37355557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics.
    Lim Kam Sian TCC; Goncalves G; Steele JR; Shamekhi T; Bramberger L; Jin D; Shahbazy M; Purcell AW; Ramarathinam S; Stoychev S; Faridi P
    Front Immunol; 2023; 14():1107576. PubMed ID: 37334365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction.
    Pak H; Michaux J; Huber F; Chong C; Stevenson BJ; Müller M; Coukos G; Bassani-Sternberg M
    Mol Cell Proteomics; 2021; 20():100080. PubMed ID: 33845167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification.
    Tretter C; de Andrade Krätzig N; Pecoraro M; Lange S; Seifert P; von Frankenberg C; Untch J; Zuleger G; Wilhelm M; Zolg DP; Dreyer FS; Bräunlein E; Engleitner T; Uhrig S; Boxberg M; Steiger K; Slotta-Huspenina J; Ochsenreither S; von Bubnoff N; Bauer S; Boerries M; Jost PJ; Schenck K; Dresing I; Bassermann F; Friess H; Reim D; Grützmann K; Pfütze K; Klink B; Schröck E; Haller B; Kuster B; Mann M; Weichert W; Fröhling S; Rad R; Hiltensperger M; Krackhardt AM
    Nat Commun; 2023 Aug; 14(1):4632. PubMed ID: 37532709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
    Freudenmann LK; Marcu A; Stevanović S
    Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics.
    Wilhelm M; Zolg DP; Graber M; Gessulat S; Schmidt T; Schnatbaum K; Schwencke-Westphal C; Seifert P; de Andrade Krätzig N; Zerweck J; Knaute T; Bräunlein E; Samaras P; Lautenbacher L; Klaeger S; Wenschuh H; Rad R; Delanghe B; Huhmer A; Carr SA; Clauser KR; Krackhardt AM; Reimer U; Kuster B
    Nat Commun; 2021 Jun; 12(1):3346. PubMed ID: 34099720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
    Bassani-Sternberg M; Pletscher-Frankild S; Jensen LJ; Mann M
    Mol Cell Proteomics; 2015 Mar; 14(3):658-73. PubMed ID: 25576301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Mass Spectrometry and Proteogenomics in the Advancement of HLA Epitope Prediction.
    Creech AL; Ting YS; Goulding SP; Sauld JFK; Barthelme D; Rooney MS; Addona TA; Abelin JG
    Proteomics; 2018 Jun; 18(12):e1700259. PubMed ID: 29314742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells.
    Jarmalavicius S; Welte Y; Walden P
    J Biol Chem; 2012 Sep; 287(40):33401-11. PubMed ID: 22869377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
    Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunopeptidomics-based identification of naturally presented non-canonical circRNA-derived peptides.
    Ferreira HJ; Stevenson BJ; Pak H; Yu F; Almeida Oliveira J; Huber F; Taillandier-Coindard M; Michaux J; Ricart-Altimiras E; Kraemer AI; Kandalaft LE; Speiser DE; Nesvizhskii AI; Müller M; Bassani-Sternberg M
    Nat Commun; 2024 Mar; 15(1):2357. PubMed ID: 38490980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-Throughput, Fast, and Sensitive Immunopeptidomics Sample Processing for Mass Spectrometry.
    Marino F; Chong C; Michaux J; Bassani-Sternberg M
    Methods Mol Biol; 2019; 1913():67-79. PubMed ID: 30666599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitive, high-throughput HLA-I and HLA-II immunopeptidomics using parallel accumulation-serial fragmentation mass spectrometry.
    Phulphagar KM; Ctortecka C; Vaca Jacome AS; Klaeger S; Verzani EK; Hernandez GM; Udeshi N; Clauser K; Abelin J; Carr SA
    bioRxiv; 2023 Mar; ():. PubMed ID: 36993564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Data-Independent Acquisition of HLA Class I Peptidomes on the Q Exactive Mass Spectrometer Platform.
    Ritz D; Kinzi J; Neri D; Fugmann T
    Proteomics; 2017 Oct; 17(19):. PubMed ID: 28834231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges and opportunities in analyzing and modeling peptide presentation by HLA-II proteins.
    ElAbd H; Bacher P; Tholey A; Lenz TL; Franke A
    Front Immunol; 2023; 14():1107266. PubMed ID: 37063883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunoprecipitation methods impact the peptide repertoire in immunopeptidomics.
    Wacker M; Bauer J; Wessling L; Dubbelaar M; Nelde A; Rammensee HG; Walz JS
    Front Immunol; 2023; 14():1219720. PubMed ID: 37545538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. optiPRM: A Targeted Immunopeptidomics LC-MS Workflow With Ultra-High Sensitivity for the Detection of Mutation-Derived Tumor Neoepitopes From Limited Input Material.
    Salek M; Förster JD; Becker JP; Meyer M; Charoentong P; Lyu Y; Lindner K; Lotsch C; Volkmar M; Momburg F; Poschke I; Fröhling S; Schmitz M; Offringa R; Platten M; Jäger D; Zörnig I; Riemer AB
    Mol Cell Proteomics; 2024 Sep; 23(9):100825. PubMed ID: 39111711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of the Cryptic HLA-I Immunopeptidome.
    Erhard F; Dölken L; Schilling B; Schlosser A
    Cancer Immunol Res; 2020 Aug; 8(8):1018-1026. PubMed ID: 32561536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification.
    Feola S; Haapala M; Peltonen K; Capasso C; Martins B; Antignani G; Federico A; Pietiäinen V; Chiaro J; Feodoroff M; Russo S; Rannikko A; Fusciello M; Koskela S; Partanen J; Hamdan F; Tähkä SM; Ylösmäki E; Greco D; Grönholm M; Kekarainen T; Eshaghi M; Gurvich OL; Ylä-Herttuala S; M Branca RM; Lehtiö J; Sikanen TM; Cerullo V
    ACS Nano; 2021 Oct; 15(10):15992-16010. PubMed ID: 34605646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ImmuneApp for HLA-I epitope prediction and immunopeptidome analysis.
    Xu H; Hu R; Dong X; Kuang L; Zhang W; Tu C; Li Z; Zhao Z
    Nat Commun; 2024 Oct; 15(1):8926. PubMed ID: 39414796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.